研究发现,停止药物治疗的心脏衰竭患者面临的风险要高得多。 Heart failure patients who stop medications face significantly higher risks, study finds.

Karolinska Institut在《循环》中发表的一项新研究表明,如果停止治疗,包括RASi、ARNi或MRA, 病情好转的心脏病患者仍面临36-38%的高死亡或住院风险。 A new study from Karolinska Institutet, published in Circulation, reveals that heart failure patients who improve still face a 36-38% higher risk of death or hospitalization if they stop their medications, including RASi, ARNi, or MRA. 这项研究以8 700多名患者为基础,支持继续使用这些药物,并建议在康复良好的患者中重新考虑乙型阻塞剂。 The research, based on over 8,700 patients, supports continuing these medications and suggests beta-blockers might be reconsidered in well-recovered patients. 该研究强调,即使心脏功能得到改善,仍有必要继续服药。 The study highlights the need to continue medication even with improved heart function.